Cornea/External Disease News

In the U.S., FDA-approved corneal cross-linking is performed with Glaukos’ iLink system as an epithelium-off procedure to slow or halt the progression of keratoconus.

Harrow announced it will begin marketing and selling Vigamox, a fluoroquinolone antibiotic eye drop for bacterial conjunctivitis, following completion of the product’s new drug application transfer.

Verséa Ophthalmics will distribute Celularity’s Biovance and Biovance 3L Ocular products for ocular surface disease treatment and ocular surgical support under the terms of an exclusive U.S. commercialization agreement.

WASHINGTON — The partnership between an optometrist and surgeon is essential to successfully managing patients with keratoconus who undergo corneal collagen crosslinking, a presenter said at Optometry’s Meeting.

Verséa Ophthalmics announced the distribution of its T-POC Total IgE Immunoassay Kit, a tear-based point-of-care test for the diagnosis and management of ocular surface disease.

The FDA approved Xdemvy, a 0.25% lotilaner ophthalmic solution, for the treatment of Demodex blepharitis, according to a press release from Tarsus Pharmaceuticals.

Do you need to hit the brakes to stop a car that is already in park? Probably not. That’s the idea behind the indication for cross-linking to treat progressive keratoconus. A patient who has stopped progressing doesn’t need to be treated.

Harrow announced that it signed agreements with Santen Pharmaceutical Co. affiliates to acquire their branded ophthalmic portfolio and also with Novaliq GmbH to acquire Vevye.

Eye care providers consider scleral lenses to be a first-choice treatment for patients with corneal irregularity, although the lenses were not favored for ocular surface disease, according to a study published in Eye & Contact Lenses.

Eye drops for glaucoma are associated with various adverse effects on the ocular surface that often lead to treatment nonadherence and poor outcomes with surgery, according to a report published in Ocular Surface.